Core Viewpoint - The article discusses the development of humanized "4D" collagen protein based on natural collagen, aiming to address the immunogenicity and pathogenic risks associated with traditional animal-derived collagen [1]. Group 1: Research and Development - The research team led by Professor Li Shuang from South China University of Technology focuses on biomimetic "honeycomb" porous structures for molecular construction, optimizing collagen triple helix sequences through gene editing [1]. - The team combines computer simulation design with cross-scale self-assembly templates to achieve a synergistic optimization of high specific surface area, strong mechanical strength, and biological activity [1]. - Techniques such as transmission electron microscopy are utilized to analyze the hierarchical structure, and in vitro cell experiments validate the biocompatibility and regenerative efficacy of the developed materials [1]. Group 2: Industry Applications - The innovative collagen material is expected to provide new biological materials for regenerative medicine, promoting upgrades in industries such as medical aesthetics and bone repair [1]. - Professor Li Shuang will present a talk titled "Molecular Design of Humanized '4D' Collagen Protein" at the SynBioCon 2025 conference, which focuses on synthetic biology and green biological manufacturing [1][14]. Group 3: Conference Details - The SynBioCon 2025 conference will be held from August 20-22 in Ningbo, Zhejiang, focusing on the intersection of AI and biological manufacturing, as well as advancements in green chemistry, new materials, future food, and agriculture [14]. - The conference will feature various activities, including a youth forum on biological manufacturing, high-level discussions on the industry, and a closed-door seminar on the "2025 Artificial Intelligence Empowering Biological Manufacturing Industry Innovation Development Blue Book" [14][15].

Core Insights - The establishment of the first synthetic biology innovation center in Northwest China at Haesfu marks a significant milestone in the field of technological innovation, enhancing the company's capabilities in synthetic biology technology commercialization [1][3] - Haesfu is recognized as an established leader in the biological manufacturing sector, focusing on the development of next-generation natural active ingredients [3][5] Summary by Sections Synthetic Biology Innovation Center - Haesfu has inaugurated a new research and development center spanning over 2,000 square meters, alongside the Shaanxi Provincial Synthetic Biology Innovation Center, indicating a robust commitment to advancing synthetic biology technology [1] Technological Advantages - The company holds numerous core patents related to synthetic biology, covering the entire chain from gene screening to efficient expression and precision fermentation [5] - Haesfu has assembled a top-tier research team led by PhD graduates from renowned universities, with an average research experience exceeding 10 years [5] - The company has developed a unique "laboratory-pilot-1000-ton factory" conversion platform, significantly shortening the product development cycle [5] Sustainability and Product Focus - Haesfu is pioneering low-carbon and energy-saving fermentation processes, aiming for 100% renewable raw materials to achieve a sustainable future [5] - The company is concentrating on high-value natural products, such as rare natural pigments, natural flavors, and new antioxidants, to build a globally competitive product portfolio [5] Upcoming Events - The 4th Synthetic Biology and Green Bio-Manufacturing Conference (SynBioCon 2025) will be held from August 20-22 in Ningbo, Zhejiang, focusing on the intersection of AI and biological manufacturing, as well as advancements in green chemistry, new materials, future food, and agriculture [4][6] - The conference will feature various activities, including a youth forum, high-level discussions, and a closed-door seminar on the "2025 Blue Book for AI Empowering Biological Manufacturing Industry Innovation Development" [4][6]

Core Viewpoint - The SynBioCon 2025 conference will focus on the integration of AI with biomanufacturing, green chemicals and new materials, future food, and future agriculture, aiming to explore the development trends of the biomanufacturing industry during the 14th Five-Year Plan period [1]. Group 1: Conference Overview - The conference will be held from August 20-22, 2025, in Ningbo, Zhejiang [1]. - It aims to promote the transfer and transformation of scientific and technological achievements, product scaling, and talent acquisition in the biomanufacturing sector [1]. Group 2: Organizers and Support Units - Organized by Ningbo Detaizhongyan Information Technology Co., Ltd. (DT New Materials) and co-organized by several academic and research institutions [2]. - Supported by various associations and alliances, including the Chinese Society of Biotechnology and the Zhejiang Synthetic Biology Industry Technology Alliance [2]. Group 3: Expert Guests - Notable experts include Zhang Xian'en, Dean of the School of Synthetic Biology at Shenzhen University, and other prominent figures from various universities and research institutes [4][5][6][7][10][12][14][18][20][22][30][32]. - The conference will feature presentations on topics such as the construction of efficient cell factories for aromatic compounds and the biomanufacturing of polyamide materials [8][11][23][31]. Group 4: Conference Agenda - The agenda includes a series of forums and discussions on topics like green chemicals, AI in biomanufacturing, and future food and agriculture [36][37]. - Activities will include a high-level roundtable on biomanufacturing and a youth forum to showcase innovative achievements in the field [36].

Core Viewpoint - Astaxanthin, a highly effective antioxidant pigment, is gaining attention for its applications in food, cosmetics, and pharmaceuticals, with a recent study demonstrating a high-yield production system using Schizochytrium for both astaxanthin and DHA [1][3]. Group 1: Research Findings - The study reported an increase in astaxanthin content from 7.56 μg/g to 55.17 μg/g through electroporation-induced color screening [2]. - Further enhancement of astaxanthin content to 374.85 μg/g was achieved by overexpressing five key genes involved in the astaxanthin synthesis pathway [2]. - The final engineered strain produced astaxanthin at a yield of 29.53 mg/L (1.913 mg/g DCW) while maintaining DHA production at 3.83 g/L, constituting 45% of total lipid content [2]. Group 2: Implications for Industry - The reported astaxanthin yield represents the highest level achieved in Schizochytrium to date, laying a foundation for the commercial scalability of astaxanthin biosynthesis [3]. - The advancements in metabolic engineering and mutagenesis techniques highlight the potential for increased production efficiency in the biotechnology sector [1][3]. Group 3: Upcoming Events - The 4th Synthetic Biology and Green Bio-Manufacturing Conference (SynBioCon 2025) will be held from August 20-22 in Ningbo, focusing on AI and bio-manufacturing, green chemistry, new materials, future food, and agriculture [6][8]. - The conference will feature various activities, including a youth forum, high-level discussions, and a closed-door seminar on AI-enabled innovations in bio-manufacturing [6][7].

Core Viewpoint - The article emphasizes the significance of high-value compounds, such as amino acids and pharmaceutical intermediates, in the field of biomanufacturing, highlighting China's role as a major producer supporting global industry development [1]. Group 1: Biomanufacturing and Synthetic Biology - High-value compounds are crucial in biomanufacturing, with China being a leading producer in this sector [1]. - A major bottleneck in synthetic biology is the insufficient availability of biological components, which can be addressed through breakthroughs in enzyme design and gene editing technologies [1]. - The research team led by Professor Feng Yan from Shanghai Jiao Tong University focuses on developing efficient biocatalysts and new synthetic pathways for artificial compounds, surpassing natural evolution [1][3]. Group 2: Research Innovations - The research team utilizes second-generation sequencing for functional analysis of large mutation libraries, enabling rapid identification of important protein scenarios [1]. - The team has developed methods to create new proteins with over 50% sequence variation, which can be applied in the production of industrial enzymes [1]. Group 3: Upcoming Conference - The SynBioCon 2025 conference will be held from August 20-22 in Ningbo, focusing on AI and biomanufacturing, as well as opportunities in green chemistry, new materials, future food, and agriculture [6]. - The conference will feature various activities, including a macro forum on biomanufacturing, youth forums, and discussions on the 2025 Blue Book for AI-enabled biomanufacturing innovation [6][7].

Core Viewpoint - The article discusses the advancements in synthetic biology, particularly focusing on optimizing yeast metabolism for carbon conservation and fixation, which is crucial for reducing CO2 emissions and achieving sustainable chemical production [3][4][5]. Summary by Sections 1. Introduction to Carbon Emissions and Synthetic Biology - The increasing use of fossil resources is leading to higher CO2 emissions, raising global concerns about climate change and the urgent need for alternative solutions to achieve carbon neutrality [4]. - Synthetic biology enables the use of inexpensive substrates, such as lignocellulose, for chemical production, thereby reducing reliance on fossil resources [4]. 2. Yeast as a Platform for Biomanufacturing - Yeast is highlighted as a robust microbial chassis for industrial biomanufacturing, capable of producing various compounds like terpenes and fatty acids [5]. - The complexity of yeast metabolism often results in unavoidable CO2 release during chemical synthesis, primarily through glycolysis, pentose phosphate pathway, and tricarboxylic acid cycle [5][6]. 3. Carbon Conservation Systems in Yeast - The article reviews recent advancements in constructing carbon conservation and fixation systems in yeast, focusing on avoiding unnecessary decarboxylation reactions to reduce carbon loss [6][8]. - Strategies include enhancing natural carboxylation reactions to promote carbon conservation, with specific examples of engineered yeast strains achieving significant improvements in product yields [8][11]. 4. Engineering Strategies and Results - Various engineering strategies are discussed, such as the non-oxidative glycolysis (NOG) pathway, which has been successfully implemented in yeast to improve carbon efficiency and product yields [10][11]. - Specific results include a 25% increase in β-farnesene yield and an 80% increase in β-carotene production through metabolic engineering [11][12]. 5. Future Directions in Low-Carbon Yeast Cell Factories - The future of biomanufacturing involves constructing low-carbon yeast cell factories that can recycle CO2 released during production and potentially utilize CO2 directly as a substrate for product synthesis [19][20]. - The article outlines the integration of carbon fixation pathways, such as the Calvin cycle and reductive glycine pathways, into yeast to enhance CO2 utilization [19][21]. 6. Conclusion - The advancements in synthetic biology and metabolic engineering present promising opportunities for developing sustainable biomanufacturing processes that significantly reduce carbon emissions and enhance product yields [3][4][5].

Core Viewpoint - The company, relying on an AI-driven synthetic biology technology platform, has developed several internationally competitive original technologies and established a rich product pipeline [1][2]. Group 1: Company Overview - Founded in 2015, the company has received over 400 million yuan in exclusive investment from Eli Lilly Asia Fund, making it one of the few synthetic biology enterprises with full-chain capabilities from R&D to production and commercialization [2]. - The company operates from its headquarters in Suzhou, with dual R&D centers in China and the U.S., and production bases in Hunan and Anhui, achieving an annual comprehensive production capacity exceeding 10,000 tons [3]. Group 2: Product and Market Development - The company has achieved stable supply and large-scale production of key raw materials, including the antibiotic raw material Florfenicol, pharmaceutical intermediates like NMN/NAD, and animal nutrition raw materials such as 25-hydroxyvitamin D3 [5]. - Its products are exported to over 20 countries globally, with a continuous increase in market share [1]. Group 3: Industry Events - The SynBioCon 2025 conference will be held from August 20-22 in Ningbo, focusing on AI-enabled biological manufacturing and featuring discussions on green chemicals, new materials, future food, and agriculture [8][9].

Core Viewpoint - Helaina, a New York-based startup, has achieved large-scale production of human lactoferrin through precision fermentation technology, with a capacity to meet the demand for 10 million servings per batch [1][3]. Company Overview - Helaina was founded in 2019 and has raised a total of $83 million, including $45 million in Series B funding [4]. - The company targets markets in women's health, sports nutrition, and digestive health, supplying effera as an ingredient to functional food, beverage, and supplement brands [4]. Product and Technology - Human lactoferrin is a bioactive protein crucial for iron balance, immune function, gut health, and normal inflammatory responses [3]. - Helaina uses genetically engineered yeast strains to express this protein, which has been self-certified as GRAS (Generally Recognized As Safe) [3]. - The company emphasizes that human lactoferrin is a superior choice compared to bovine lactoferrin, as it does not trigger antibody responses in humans [3]. Market Potential - The company sees the opportunity to create a new category in the market, focusing on clinically validated high-value bioactive substances [7]. - Helaina's products are positioned to address common issues such as iron deficiency in women and inflammation in sports nutrition [4][5]. Research and Development - Helaina conducts both internal research and clinical trials with partners to validate the efficacy of its products [6]. - The company aims to explore the significant impacts of low-dose supplementation of human lactoferrin and its potential benefits in muscle recovery when combined with creatine [6]. Strategic Partnerships - Helaina has established collaborations with various commercial partners, including Kroma Wellness and Mitsubishi International Food Ingredients, to expand its product offerings [1][4].

Core Viewpoint - The SynBioCon 2025 conference will focus on the integration of AI with biomanufacturing, green chemicals and new materials, future food, and future agriculture, aiming to explore the development trends of the biomanufacturing industry during the 14th Five-Year Plan period [1]. Organizers and Support Units - The conference is organized by Ningbo Detaizhong Research Information Technology Co., Ltd. and supported by various institutions including Peking University Ningbo Institute of Ocean Medicine and the China Society of Biotechnology [2]. Expert Guests - Notable experts include Zhang Xian'en, Dean of the School of Synthetic Biology at Shenzhen University, and other prominent figures from various universities and research institutes who will share insights on biomanufacturing innovations [4][5][6][7]. Conference Agenda - The event will feature a series of forums and discussions, including a high-level roundtable on biomanufacturing, thematic forums on green chemicals and new materials, AI in biomanufacturing, and future food and agriculture [36][37]. Key Topics of Discussion - Topics will cover the construction of efficient cell factories for aromatic compounds, biomanufacturing of polyamide materials, and advancements in enzyme engineering for low-carbon biomanufacturing [8][11][27]. Networking and Collaboration - The conference aims to facilitate technology transfer, product scaling, and talent acquisition within the biomanufacturing sector, promoting collaboration among industry leaders, researchers, and government entities [1]. Event Details - The conference will take place from August 20 to 22, 2025, in Ningbo, Zhejiang, featuring registration, networking opportunities, and a showcase of technological achievements in biomanufacturing [1][36].

Core Viewpoint - The company Jindawei expects a significant increase in net profit for the first half of 2025, driven by sales growth in Coenzyme Q10, Vitamin A, and domestic health products [1][3]. Group 1: Financial Performance - Jindawei anticipates a net profit attributable to shareholders of 221 million to 260 million yuan for the first half of 2025, representing a year-on-year growth of 70% to 100% [1]. - The expected non-net profit is projected to be between 220 million and 259 million yuan, also reflecting a year-on-year increase of 70% to 100% [1]. - The basic earnings per share are estimated to be between 0.36 yuan and 0.42 yuan [1]. Group 2: Business Overview - Jindawei primarily engages in the research, production, and sales of nutritional health foods and feed additives, with a high export ratio for raw materials [3]. - The company operates in both upstream raw material supply and downstream brand operation, making it a rare full-industry chain player in the health food sector [5]. Group 3: Product Development - In the raw material sector, Jindawei utilizes synthetic biology for large-scale production of products like Coenzyme Q10, NMN, and DHA, among others [4]. - The company holds the largest global market share in Coenzyme Q10, benefiting from cost and scale advantages [4]. - Jindawei is focused on reducing production costs for products like astaxanthin and DHA to enhance market competitiveness [4]. Group 4: Marketing Strategy - The company plans to leverage market insights and resource integration to develop product strategies and create market-leading products [6]. - Jindawei aims to enhance its operational capabilities and increase its market share in domestic health products by utilizing its advantages in raw material research and production [5].